In chronic lymphocytic leukemia (CLL), immunotherapy, such as anti-PD1/CTLA-4 immunotherapy, shows little benefits in patient survival, and the higher expression of LAG3 in CLL contributes to tumor immune escape, as well as indicates poor prognosis. The gene discussed is LAG3; the disease is B-cell chronic lymphocytic leukemia.